STAT+: Dutch antitrust regulators probe Biogen over test for its MS drug

AI Summary

Dutch antitrust regulators are investigating whether Biogen abused its dominant position in the market for multiple sclerosis treatments and related blood tests. The probe concerns alleged anticompetitive conduct; no finding of wrongdoing is reported.

Dutch anti-trust regulators are investigating allegations that Biogen may have abused its dominant position in the market for MS treatments and associated blood tests.